Grants and Contributions:
Title:
Providence COVID-19 Vaccine Development - Stage 2
Agreement Number:
976618
Agreement Value:
$8,660,000.00
Agreement Date:
Jul 23, 2021 - Nov 30, 2022
Description:
The Firm is Canada's leader in mRNA therapeutics and this project's main goal is to continue the development of PTX-COVID19-B by conducting a Phase II clinical trial with the goal of commercializing a made-in-Canada COVID-19 mRNA vaccine and the development and validation of mRNA vaccines targeting COVID-19 Variants of Concern.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Calgary, Alberta, CA T2Z 3P2
Reference Number:
172-2021-2022-Q2-976618
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
738045079
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 60,000 dollars. Calgary Midnapore 48008
Amendment Date
Mar 30, 2022
Recipient's Legal Name:
Providence Therapeutics Holdings Inc.
Federal Riding Name:
Calgary Shepard
Federal Riding Number:
48011
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254
Amendments: